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Background
From 1995 to 2004, the estimated incidence of tuber-
culosis (TB) increased steadily around the world, with an 
excess in sub-Saharan Africa, in relation with the 
emer  gence and expansion of the HIV epidemic [1]. Th  e 
estimated TB incidence has been slowly declining since 
then, at a rate of 1% per year, making it impossible to 
reach the 2050 TB elimination target, deﬁ  ned as less than 
one TB case per million population [2]. Th  ere were an 
estimated 9.4 million incident TB cases in the world in 
2009, of which an estimated 1.1 million (12%) were living 
with HIV; 1.7 million deaths were also estimated, includ-
ing 380,000 among HIV individuals [3]. TB con  tinues to 
be a leading cause of deaths among people living with 
HIV, accounting for one-ﬁ  fth of the 1.8 million AIDS-
related deaths in 2009.
While HIV testing among TB patients has rapidly 
scaled up since 2002, the uptake of antiretroviral therapy 
(ART) among TB patients living with HIV is 
unsatisfactory, with only 140,000 TB patients with HIV 
co-infection placed on ART worldwide in 2009 [3]. 
Prevention and treatment of TB among people living 
with HIV remains limited: only 5% of the estimated 33.3 
million people living with HIV (about 1.7 million) were 
screened for TB in 2009, and less than 1% (88,000) of 
those found without active TB were enrolled on isoniazid 
preventive therapy (IPT) [3]. Th  ese percentages are still 
very far from the 100% and 50% targets set for 2015 in the 
Global Plan to Stop TB 2011-2015 [4]. To boost TB 
control activities in relation with HIV, and reach these 
targets, important operational research questions need to 
be urgently addressed.
Th  e aim of this paper is to review and present the 
priority operational research questions to improve the 
prevention, diagnosis and treatment of TB among people 
living with HIV, including innovative models of service 
delivery for collaborative TB/HIV activities. Several 
deﬁ  nitions for operational research have been proposed 
[5-8]. For the purpose of this paper, we deﬁ  ned opera-
tional research according to its ultimate objectives, that 
are: (i) to improve programme performance and out-
comes; (ii) to assess the feasibility, eﬀ  ectiveness or impact 
of new strategies or interventions for TB control; or (iii) 
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speciﬁ  c interventions [9].
Methods
We used a variety of sources of information. We reviewed 
PubMed and Web of Science databases using a combi-
nation of “tuberculosis” and “HIV” with the following key 
words: drug-resistant tuberculosis, anti-tuberculosis 
treatment, treatment of latent infection, antiretroviral 
therapy, infection control, laboratory services, childhood 
tuberculosis, pregnant women, community, programme 
evaluation, and opera  tional research.
We also reviewed reports of expert consultations and 
other research-related meetings with a focus on 
operational research aspects organized by the World 
Health Organization (WHO) and the Stop TB Partner-
ship in 2009-2010 [10-16]. Th  e objectives and proceed-
ings of these meetings included questions addres  sing the 
translation gaps in implementing existing and new tools 
and technologies within TB services, as well as questions 
on how operational research could best inform policy 
decision making at national, regional and global levels. 
Th  e meetings and documents also deﬁ  ned key areas of 
TB control for which various research questions were to 
be addressed as priorities, taking into account the various 
elements of time, place and person, and issues of 
relevance and feasibility [16]. In one document, the TB/
HIV research questions were identiﬁ   ed by various 
experts and prioritized using a scoring system that used a 
set criteria of eﬀ  ectiveness, deliverability, answerability and 
equity [17].
We have re-examined the documents for the aspects of 
operational research and present our ﬁ   ndings in the 
following key areas: (i) prevention of TB among people 
living with HIV; (ii) implementation of infection control 
measures; (iii) early diagnosis and treatment of TB in 
people living with HIV; (iv) service delivery of 
collaborative TB/HIV activities; (v) reducing mortality 
among TB patients living with HIV; and (vi) childhood 
TB and HIV.
Key areas of operational research
Th  e WHO policy on collaborative TB/HIV activities 
recommends a combination of measures to reduce the 
burden of TB among people living with HIV [18]. Th  ese 
measures include intensiﬁ  ed TB case ﬁ  nding, prevention 
of TB with IPT and ART, and eﬃ   cient infection control, 
which are branded as the Th  ree I’s for HIV/TB. Th  eir 
implementation requires sound policy and a programme 
environment that gives due consideration to the local 
context, the epidemiology of TB and HIV, and the status 
of health systems and infrastructure that will determine 
the service delivery models. In addition to the operational 
diﬃ   culties con  fronted in providing quality and eﬀ  ective 
interventions, the cultural and system-wide diﬀ  erences 
between TB and HIV programmes, care providers and 
partner organi  za  tions may have contributed to the 
limited implementation of collaborative TB/HIV 
activities.
Operational research plays a key role in addressing 
these challenges and optimizing and scaling up preven-
tion, diagnosis and treatment of TB among people living 
with HIV through eﬀ   ective service delivery models, 
including community-based interventions. Table 1 sum-
mar  izes the operational research priorities to improve 
the implementation of collaborative TB/HIV programme 
activities [16, 17, 19]. Th  e ultimate objective of each 
operational research question is presented, as well as how 
it inﬂ  uences the design and methodology of the research, 
the setting where it is conducted, the degree of 
generalizability of the results, and the ultimate relevance 
for TB control from local to global level [9].
Prevention of TB among people living with HIV
Meta-analyses of randomized controlled trials have 
shown that IPT reduces the risk of active TB by 33% in 
people living with HIV, irrespective of skin test result, 
and by up to 64% in those with a positive tuberculin skin 
test [20, 21]. Despite the substantial amount of clinical 
research that showed the beneﬁ  ts of IPT among people 
living with HIV, several barriers and operational challen-
ges have hampered its roll out [22]. One of these is the 
diﬃ   culty of reliably excluding active TB before preventive 
therapy, with subsequent concern about the possibility of 
selecting for isoniazid resistant M. tuberculosis strains 
and eventually multi-drug-resistant strains [23]. WHO 
has recently developed simpliﬁ  ed TB screening algorithms 
for adults and children living with HIV that will promote 
the delivery of IPT for people living with HIV[24].
Although the adult algorithm was based on an indi  vidual 
participant data meta-analysis of more than 9000 patients 
[25], the children algorithm mostly relied on expert 
opinion, due to lack of evidence. Concomitant to 
intensifying the search for a simple and rapid TB 
diagnostic tool, the implementation of these algorithms 
need to be scaled up and their feasibility, eﬀ  ectiveness and 
impact investigated by national AIDS and TB programmes.
Clinicians are faced with challenges on how to maintain 
adherence to IPT: studies from Malawi, South Africa and 
Zambia have shown that adherence varies from 24% to 
59% [26]. Concerns also exist on the need and feasibility 
of monitoring IPT in terms of toxicity and occurrence of 
TB disease [27]. Recent data from more than 24,000 
South African patients showed, however, very low rates 
of IPT-related adverse events (particularly clinical hepato-
toxicity: 0.07%), and suggested that monitoring based on 
clinical symptoms was suﬃ   cient [28]. Th  ese  encouraging 
results need to be conﬁ  rmed in other populations.
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Page 5 of 12Another important question is the duration of 
preventive therapy. Results from two recent clinical trials 
from Botswana [29] and South Africa [30] suggest an 
increased beneﬁ  t of IPT when given for 36 months or 
longer, compared with six months, particularly in people 
who are tuberculin skin test positive. However, a clinical 
trial reported no diﬀ  erence between 36 and six months of 
extended use of isoniazid and ethambutol in India [31]. 
Th   e feasibility of life-long IPT under routine conditions 
and the factors related to it, as well as the timing of 
initiation in relation to ART, which also greatly reduces 
TB incidence [32], need to be further investigated. From 
a programme perspective, it is important to determine 
which programmes or services (HIV, TB, mother and 
child health, or others) will best coordinate nationwide 
implementation of IPT and ensure that it is included in 
the comprehensive package of care for people living with 
HIV [24].
Implementation of infection control measures
In addition to preventive chemotherapy, eﬃ   cient infec-
tion control measures at facility level are crucial to pre-
vent the transmission of M. tuberculosis among people 
living with HIV [33]. Th  ese include: administrative 
control measures, such as triage; separation of infectious 
cases; control of pathogens’ spread and reduced hospital 
stay; environmental control with natural or mechanical 
ventilation systems and the use of ultraviolet germicidal 
irradiation; and personal protective protection for health-
care workers. Th  e identiﬁ   cation of the best mix of 
infection control measures to be implemented and of the 
best means to monitor these in healthcare facilities 
(including suitable indicators and methods for detecting 
the concentration of viable M. tuberculosis droplet nuclei 
in room air) is needed. It will assist TB and AIDS 
programmes in improving their performance and evalu-
at  ing their contribution to reducing TB transmission.
Early diagnosis and treatment of TB among people living 
with HIV
Delay in TB diagnosis may in part explain the high 
mortality rates among people living with HIV [34]. Th  e 
eﬀ  ectiveness, impact and modalities of scaling up existing 
tools and strategies, such as specimen culturing and 
clinical algorithms [35], need to be assessed. Similarly, 
the newly developed, fully automated, cartridge-based 
nucleic ampliﬁ  cation assay, Xpert MTB/RIF, which can 
detect drug susceptible and rifampicin resistant TB in 
less than two hours, needs to be rapidly introduced and 
adapted on a large scale in health services. Th  e  sensitivity 
of a single Xpert MTB/RIF test was 98.2% and 72.5% in 
smear-positive and smear-negative disease, respectively, 
and 99.1% in rifampicin resistant TB, and was not 
aﬀ  ected by the patient’s HIV status [36]. WHO has now 
recommended Xpert MTB/RIF as the initial diagnostic 
test for all people living with HIV, as well as for those 
suspected of having multi-drug-resistant TB [37].
Th   e algorithms for the diagnosis of HIV-associated TB, 
both for ambulatory and seriously ill patients, were 
revised to include Xpert MTB/RIF and to assist in its 
implementation in HIV prevalent settings (Figures 1 and 
2) [38]. Operational research is crucially needed to assess 
the feasibility and validity of these revised algorithms. 
Th  ere is an urgent need for collecting further evidence 
for scaling up Xpert MTB/RIF under programmatic con-
ditions at the various levels of health services, including 
HIV care facilities, under diﬀ  erent epidemiological and 
resource conditions. Real-time cost-eﬀ  ectiveness data are 
also needed to inform policy.
Th  e use of ART has been associated with up to 95% 
reduction in mortality risk among TB patients living with 
HIV [39], including those with drug-resistant TB [40, 41]. 
Combined ART and TB treatment is more protective 
than delaying ART after completion of TB treatment 
[42]. Th   e CAMELIA randomized control trial conducted 
in Cambodia among 661 HIV-infected TB patients with a 
median CD4 count of 25 cells/mm3 found a 34% reduc-
tion in mortality associated with the early initiation of 
ART two weeks after onset of TB treatment, compared 
with eight weeks after onset [43]. Similarly the STRIDE 
and SAPIT trials showed that combined and earlier ART 
and TB treatment (two to four weeks after TB treatment 
initiation) reduced deaths and AIDS-related events by 
42% and 68%, respectively, among those with CD4 counts 
of less than 50 cells/mm3 when compared with ART 
initiation within eight to 12 weeks of TB treatment 
[44,45]. Th   ese results conﬁ  rm current WHO recom  men-
dations to start ART as soon as possible in the course of 
TB treatment [46], especially in people with profound 
immunosuppression. Operational research to inform 
national AIDS and TB programmes on how best to imple-
ment these recommendations and scale up the uptake of 
ART in TB patients living with HIV is urgently needed and 
should include the assessment of various service delivery 
models for collaborative TB/HIV activities.
A prerequisite for improved early diagnosis and treat-
ment of TB among people living with HIV is knowledge 
of HIV status. HIV testing for those with conﬁ  rmed and 
presumptive TB and their contacts yields a high number 
of new diagnoses of HIV [47-50], and should be en-
couraged. Any innovative measure to increase the uptake 
of HIV testing, such as the home-based rapid test [51], 
needs to be assessed and standardized for TB patients, 
TB suspects and their relatives.
Service delivery of collaborative TB/HIV activities
Integration of TB and HIV services to deliver collabora-
tive TB/HIV activities is important in settings where 
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are in need of ART. A recent systematic review has 
shown that diﬀ  erent models of integration of services are 
being implemented: (i) TB services refer patients for HIV 
testing and treatment; (ii) HIV services refer people 
living with HIV for tuberculosis screening and treatment; 
(iii) TB services test patients for HIV and refer them for 
treatment; (iv) HIV services screen for tuberculosis but 
refer patients for treatment; and (v) TB and HIV services 
are provided at a single facility [52]. However, the best 
delivery model is unknown and it is unlikely that a “one-
size-ﬁ  ts-all” approach will work.
Ways to decentralize TB and HIV services into primary 
healthcare, as well as mother and child healthcare facili-
ties, should also be investigated. Operational research is 
needed to provide evidence on best service delivery 
models and on their eﬀ  ectiveness, so as to enhance the 
uptake of TB and HIV prevention, diagnosis and 
treatment for people aﬀ  ected by, and at risk for, both 
diseases. Th   e impact of the models on patients’ outcomes 
also needs to be investigated [52]. Speciﬁ  c  attention 
should be paid to evaluating these questions in special 
populations, such as children, women, prisoners and 
injecting drug users. Particular emphasis is needed for 
the integrated delivery of TB and HIV services with 
harm-reduction services in those settings where drug use 
is fuelling the HIV epidemic.
Community participation for enhanced TB case ﬁ  nding 
and early HIV detection to reduce delay in initiation of 
TB and HIV care also needs to be further investigated by 
research stakeholders, including national TB and AIDS 
programmes. TB control in settings with high HIV 
Figure 1. Algorithm for the diagnosis of tuberculosis in ambulatory HIV-positive patients using Xpert MTB/RIF. 1Among adults and 
adolescents living with HIV, a TB suspect is defi  ned as a person who reports any one of current cough, fever, weight loss or night sweats. Among 
children living with HIV, a TB suspect is defi  ned as a person who reports one of poor weight gain, fever, current cough, or history of contact with 
a TB case. 2In all persons with unknown HIV status, HIV testing should be performed according to national guidelines. In patients who are HIV 
negative or remain HIV unknown (e.g., refusal), a TB suspect is defi  ned according to national case defi  nitions. A person with unknown HIV status can 
still be classifi  ed as HIV-positive if there is strong clinical evidence of HIV infection. 3The danger signs include any one of: respiratory rate >30/min, 
temperature >39°C, heart rate >120/min and unable to walk unaided. 4CPT = cotrimoxazole preventive therapy. 5ART = antiretroviral therapy. All TB 
patients living with HIV are eligible for ART irrespective of CD4 count. Start TB treatment fi  rst, followed by ART as soon as possible within the fi  rst 8 
weeks of TB treatment. See ART guidelines. 6In low MDR-TB prevalence settings, a confi  rmatory test for rifampicin resistance should be performed. 
See MDR-TB Xpert MTB/RIF algorithm. 7A chest x-ray can assist with the diagnosis of extra-pulmonary TB (e.g., pleural, pericardial) and help assess for 
other etiologies of respiratory illness.  It should only be performed in those settings where the quality of the fi  lm and its interpretation are assured. 
8Antibiotics (except fl  uoroquinolones) to cover both typical and atypical bacteria should be considered. 9An HIV treatment assessment includes 
WHO clinical staging and/or CD4 count to assess eligibility for antiretroviral therapy. See ART guidelines. 10PCP= Pneumocystis jirovecii pneumonia.
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Page 7 of 12prevalence will not succeed without reaching out into the 
community [53], and innovative ways of doing so, such as 
using mobile vans [54] or health extension workers [55], 
need to be tested under routine conditions. Identiﬁ  cation 
of the best ways that TB and HIV/AIDS programmes 
could bring TB prevention, diagnosis and treatment 
services for both drug-susceptible and drug-resistant TB 
closer to the community through innovation and decen-
tralization of service is crucial. Finally, cost-eﬀ  ectiveness 
analyses of the various healthcare- and community-level 
service delivery models are important to maximize value 
for money in a time of scarce resources [56].
Reducing mortality among TB patients living with HIV
In addition to ART, cotrimoxazole preventive therapy 
(CPT) has been found to reduce mortality in people 
living with HIV and treated for TB [57]. However, the 
provision of both ART and CPT has not been fully scaled 
up, and operational research can assist in determining 
the best ways to do so. Operational research can also help 
determine if there are other context-dependant and 
modiﬁ  able risk factors, such as undiagnosed multi-drug-
resistant TB, malnutrition and poor treatment adherence, 
that are associated with death among patients living with 
HIV on TB treatment despite receiving ART and CPT. 
Figure 2. Algorithm for the diagnosis of tuberculosis in seriously ill HIV-positive patients using Xpert. 1Seriously ill refers to the presence 
of danger signs, including: respiratory rate >30/min, temperature >39°C, heart rate >120/min and unable to walk unaided. 2Among adults and 
adolescents living with HIV, a TB suspect is defi  ned as a person who reports any one of current cough, fever, weight loss or night sweats. Among 
children living with HIV, a TB suspect is defi  ned as a person who reports one of poor weight gain, fever, current cough, or history of contact with a 
TB case. 3In all persons with unknown HIV status, HIV testing should be performed according to national guidelines. In high HIV prevalent settings, 
seriously ill patients should be tested using Xpert MTB/RIF as the primary diagnostic test regardless of HIV status. 4The highest priority should be to 
provide the patient with life-sustaining supportive therapy, such as oxygen and parenteral antibiotics. If life-sustaining therapy is not available at 
the initial point of care, the patient should be transferred immediately to a higher level facility before further diagnostic testing. 5Antibiotics (except 
fl  uoroquinolones) to cover both typical and atypical bacteria should be considered. 6PCP= Pneumocystis jirovecii pneumonia. 7CPT = cotrimoxazole 
preventive therapy. 8ART = antiretroviral therapy. All TB patients living with HIV are eligible for ART irrespective of CD4 count. Start TB treatment fi  rst, 
followed by ART as soon as possible within the fi  rst 8 weeks of TB treatment. See ART guidelines. 9In low MDR-TB prevalence setting, a confi  rmatory 
test for Rifampicin resistance should be performed. See MDR-TB algorithm. 10An HIV treatment assessment includes WHO clinical staging and/or 
CD4 count to assess eligibility for antiretroviral therapy. See ART guidelines. 11Additional investigations for TB may include chest x-ray, liquid culture 
of sputum, lymph node aspiration for acid-fast bacilli microscopy and culture, abdominal ultrasound.  Non-tuberculosis mycobacterial infection 
should be considered in the diff  erential diagnosis of patients who have a negative Xpert but a sputum or extra-pulmonary specimen with acid-fast 
bacilli.
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identify risk factors associated with mortality rates at 
ﬁ  xed time points.
Childhood TB and HIV
Most infants born to HIV-infected mothers still receive 
the Bacille Calmette-Guérin (BCG) vaccine, as HIV 
infection is usually not ruled out in the ﬁ  rst weeks of life. 
BCG can cause disseminated mycobacterial disease in 
HIV-infected children, including those on ART [58], and 
its eﬃ   cacy has been questioned in HIV-infected infants 
up to one year of age [59]. While waiting for a better and 
safer vaccine to prevent TB, the role of the BCG vaccine 
in infants living with HIV should be further investigated. 
Similarly, while isoniazid preventive therapy has been 
found to reduce the risk of TB disease by 72% and 
mortality by 56% in children living with HIV [60], little is 
known about the beneﬁ  t of IPT in the context of ART, 
the optimal duration and regimen for preventive TB 
therapy, the duration of protective eﬀ  ect, and the long-
term adverse events among children living with HIV.
In the absence of mycobacterial conﬁ  rmation, the diag-
nosis of childhood TB relies on clinical features, exposure 
history, tuberculin skin test, relevant investigations for 
suspected pulmonary or extrapulmonary TB, and HIV 
testing in areas of high HIV prevalence [61]. Th   e use of 
Xpert MTB/RIF on sputum samples and others speci-
mens to diagnose TB among children living with HIV 
should be urgently evaluated. Preliminary results show 
that Xpert MTB/RIF performs better in those children 
living with HIV than in HIV-negative children (Catharina 
Boehme, personal communication).
Issues related to combined TB and ART treatment in 
children with HIV, such as optimal time to initiate ART, 
drug interactions, overlapping side eﬀ  ects, and diagnosis 
and management of immune reconstitution inﬂ  amma  tory 
syndrome, have been poorly investigated. Current recom-
men  dations are often drawn from data from HIV-un-
infected children and adults [62] or rely on expert opinion. 
Th   ere is an urgent need to conduct operational research to 
assess the feasibility, eﬀ   ectiveness and impact of these 
recom  mendations and further inform national and inter-
national guidance on TB treatment, but also prevention 
and diagnosis in infants and children living with HIV.
Lastly, control of HIV-associated TB in children will not 
succeed without tackling their mothers. In the prevention 
of mother to child transmission of HIV, prevention of TB 
is crucial since maternal TB has been associated with 
increased vertical transmission of HIV [63].
Other critical areas
Monitoring and evaluation
Functional TB/HIV monitoring and evaluation system 
with standardized indicators is crucial to inform policy 
and programming. Th  e capacity to cross check and 
reconcile accurate data between TB and AIDS pro-
grammes will depend on the existence of standardized 
and integrated recording and reporting formats (patient 
cards, clinical ﬁ   les and registers), and will assist in 
identifying recording and reporting gaps so as to improve 
the monitoring and evaluation of collaborative TB/HIV 
activities. Eﬀ  ective and regular joint supervision by TB 
and AIDS programmes may greatly improve the process.
Access to care
Th   ere are several structural and social barriers of access 
to TB and HIV services for people living with HIV [64]. 
Qualitative research to better understand the barriers to 
TB and HIV care for people living with HIV, their 
children and their families, both from a patient and 
health  care worker’s perspective, is important in improv-
ing access to and use of diagnostic services.
Civil society and public-private sector engagement
Enhancing the role of civil society organizations in imple-
mentation and research [65] and the promotion of 
sustainable collaboration between all public and private 
practitioners for TB care and control are essential for 
scaling up collaborative TB/HIV activities [66]. Th  e  best 
way to achieve these goals needs to be worked out.
Capacity building for operational research
Finally, enhanced capacity building for operational 
research within programmes in countries with high 
burdens of TB and HIV diseases and a transfer of north-
to-south expertise is urgently needed [67]. Trainings and 
courses on operational research for collaborative TB/HIV 
activities need to take this into consideration, and ensure 
that there is leadership by researchers, programme 
managers and other stakeholders based in the countries 
aﬄ     icted by the dual epidemic. Th  is will result in 
ownership of the research that will facilitate its 
translation into policy and programming.
Conclusions
Promoting research is a key component of the Stop TB 
Strategy, which includes conducting “programme-based 
operational research” and “research on introducing new 
tools into practice” [68]. Th   e importance of programme-
based operational research is increasingly recognized, as 
exempliﬁ  ed through the insertion of a concise Opera-
tional Research section in the new Global Plan to Stop 
TB 2011-2015 [4], and was recently identiﬁ  ed as a major 
area in which global action is urgently needed [69].
In this paper, we have reviewed the main operational 
research priorities that need to be addressed to improve 
the implementation of collaborative TB/HIV programme 
activities in areas aﬀ  ected by both epidemics [16,17,19]. 
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answering the translation gaps in implementing combi-
na  tions of existing and new tools and technologies to 
improve the prevention, early diagnosis and prompt 
treatment of TB among people living with HIV. Optimal 
control of TB in high HIV burden areas requires strong 
collaborative TB/HIV interventions through sound policy 
and programme environments that give due considera-
tion to the local context and the respective epidemiology 
of TB and HIV. Moreover, since both TB and HIV control 
activities are placed within the larger frame of health 
services, due consideration should also be given to the 
health system infrastructure, as it has implications in 
terms of general health system functions (e.g., ﬁ  nances, 
regulations, policy development, management of human 
resources, procurement of drugs and supplies, and 
maintenance of health infrastructure) [70]. It is therefore 
important to address these questions within the larger 
context of health services research to identify measures 
that would facilitate wider uptake and scaling up of 
collaborative TB/HIV interventions for prevention, diag-
nosis and treatment, through eﬀ  ective service delivery 
models, including community-based interventions [71]
In this respect, national TB and AIDS pro  grammes 
should develop their operational research agendas and 
conduct the research they consider crucial for improving 
TB and HIV control in their settings in collaboration 
with research stakeholders. Support from academic 
institutions and international organizations is essential 
for implementing research questions that aim to assess 
new tools and strategies and to inform global policy, as 
well as to build local capacity in conducting operational 
research. Financial resources to implement these 
operational research questions should be mobilized and 
drawn from existing funding mechanisms (among others, 
the Global Fund to ﬁ  ght AIDS, Tuberculosis and Malaria, 
the President’s Emergency Plan for AIDS Relief, and the 
Bill & Melinda Gates Foundation), and new funding 
mechanisms need to be sought. Enhancing fund 
allocation for operational research by national govern-
ments of countries highly aﬀ  ected by both diseases and 
ensuring the expedited translation of results of the 
research into policy and programming are points of 
equally crucial importance.
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